Belite Bio Announces Oral Presentations at Two Upcoming Medical Conferences

SAN DIEGO, Sept. 28, 2026 (GLOBE NEWSWIRE) -- Belite Bio, Inc (NASDAQ: BLTE) (“Belite Bio(®)” or the “Company”), a clinical-stage drug development company focused on advancing novel therapeutics targeting degenerative retinal diseases that have significant unmet medical needs, today announced that its data will be presented at the Euretina Innovation Spotlight (EIS) being held on September 30, 2026, and Euretina being held on October 1-4, 2026, in Vienna, Austria.

EIS Presentation Details Session: EURETINA Innovation Spotlight – Inherited and Rare Retinal Diseases Title: Belite Bio Company Overview Presenter: Hendrik Scholl, M.D., Chief Medical Officer, Belite Bio Date and Time: September 30, 2026, 2:28 – 3:06 p.m. CEST Location: Vienna Congress & Convention Center, Room 1/Hall A